Top

Published in:

01-12-2019 | Topic Paper

Treatment of the primary tumor in metastatic prostate cancer

Authors: Ye Yuan, Amar U. Kishan, Nicholas G. Nickols

Published in: World Journal of Urology | Issue 12/2019

Abstract

The cornerstone of treatment for metastatic prostate cancer patients has been conventional androgen deprivation therapy, with additional systemic therapy initiated only after castration resistance, and local therapy reserved for palliation. Compelling results from modern trials challenge this paradigm, arguing for initiating escalated hormone therapy and/or chemotherapy during the castration-sensitive disease state for many patients. Furthermore, modern radiotherapy techniques allow for local control of disease with low risk of toxicity. Finally, new PET probes with enhanced sensitivity and accuracy are likely to become a part of routine staging and will lead to an increased incidence of patients with metastatic disease at presentation, with a shift toward identification of patients with limited metastatic disease. As such, the landscape is primed for investigations aimed to explore the role of primary tumor therapy for patients with metastatic prostate cancer. We review the existing data evaluating primary tumor therapy for patients with metastatic prostate cancer and describe ongoing clinical trials testing the hypothesis that primary tumor therapy may benefit patients with metastatic prostate cancer.

Mohler JL, Lee RJ, Antonarakis ES et al (2018) National Comprehensive Cancer Network. Prostate Cancer (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 16 July 2018

Huggins C, Hodges CV (2002) Studies on prostatic cancer. J Urol 167:948–951. https://doi.org/10.1016/S0022-5347(02)80307-X CrossRefPubMed

Schally AV, Arimura A, Kastin AJ et al (1971) Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 173:1036–1038CrossRefPubMed

James ND, Spears MR, Clarke NW et al (2015) Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol 67:1028–1038. https://doi.org/10.1016/j.eururo.2014.09.032 CrossRefPubMed

Nguyen PL, Alibhai SMH, Basaria S et al (2015) Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67:825–836. https://doi.org/10.1016/j.eururo.2014.07.010 CrossRefPubMed

Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352–360. https://doi.org/10.1056/NEJMoa1704174 CrossRefPubMed

James ND, de Bono JS, Spears MR et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377:338–351. https://doi.org/10.1056/NEJMoa1702900 CrossRefPubMedPubMedCentral

Kim M-Y, Oskarsson T, Acharyya S et al (2009) Tumor self-seeding by circulating cancer cells. Cell 139:1315–1326. https://doi.org/10.1016/j.cell.2009.11.025 CrossRefPubMedPubMedCentral

Gundem G, Van Loo P, Kremeyer B et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520:353–357. https://doi.org/10.1038/nature14347 CrossRefPubMedPubMedCentral

10.

Kaplan RN, Rafii S, Lyden D (2006) Preparing the “soil”: the premetastatic niche. Cancer Res 66:11089–11093. https://doi.org/10.1158/0008-5472.CAN-06-2407 CrossRefPubMedPubMedCentral

11.

Cai C, Balk SP (2011) Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer 18:R175–R182. https://doi.org/10.1530/ERC-10-0339 CrossRefPubMed

12.

Heidenreich A, Pfister D, Porres D (2015) Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol 193:832–838. https://doi.org/10.1016/j.juro.2014.09.089 CrossRefPubMed

13.

Won ACM, Gurney H, Marx G et al (2013) Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int 112:E250–E255. https://doi.org/10.1111/bju.12169 CrossRefPubMed

14.

Steinberg GD, Epstein JI, Piantadosi S, Walsh PC (1990) Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol 144:1425–1432CrossRefPubMed

15.

Flanigan RC, Salmon SE, Blumenstein BA et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655–1659. https://doi.org/10.1056/NEJMoa003013 CrossRefPubMed

16.

Mickisch GH, Garin A, van Poppel H et al (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358:966–970CrossRefPubMed

17.

Méjean A, Ravaud A, Thezenas S et al (2018) Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 379:417–427. https://doi.org/10.1056/NEJMoa1803675 CrossRefPubMed

18.

Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259. https://doi.org/10.1200/JCO.2002.20.5.1248 CrossRefPubMed

19.

Fader AN, Rose PG (2007) Role of surgery in ovarian carcinoma. J Clin Oncol 25:2873–2883. https://doi.org/10.1200/JCO.2007.11.0932 CrossRefPubMed

20.

du Bois A, Reuss A, Pujade-Lauraine E et al (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115:1234–1244. https://doi.org/10.1002/cncr.24149 CrossRefPubMed

21.

Choti MA, Sitzmann JV, Tiburi MF et al (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766CrossRefPubMedPubMedCentral

22.

Pawlik TM, Scoggins CR, Zorzi D et al (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241: 715–722:discussion 722–724

23.

Pitroda SP, Khodarev NN, Huang L et al (2018) Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. https://doi.org/10.1038/s41467-018-04278-6 CrossRefPubMedPubMedCentral

24.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. PubMed NCBI. https://www.ncbi.nlm.nih.gov/pubmed/27380959. Accessed 2 Oct 2018

25.

Harris E, Barry M, Kell MR (2013) Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival. Ann Surg Oncol 20:2828–2834. https://doi.org/10.1245/s10434-013-2998-2 CrossRefPubMed

26.

Badwe R, Hawaldar R, Nair N et al (2015) Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol 16:1380–1388. https://doi.org/10.1016/S1470-2045(15)00135-7 CrossRefPubMed

27.

DallEra MA, Lo MJ, Chen J et al (2018) Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer: local therapy in advanced prostate cancer. Cancer 124:1921–1928. https://doi.org/10.1002/cncr.31285 CrossRef

28.

Kelly SP, Anderson WF, Rosenberg PS, Cook MB (2018) Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States. Eur Urol Focus 4:121–127. https://doi.org/10.1016/j.euf.2017.10.014 CrossRefPubMed

29.

Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM (2016) Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis 19:395–397. https://doi.org/10.1038/pcan.2016.30 CrossRefPubMed

30.

Calais J, Cao M, Nickols NG (2018) The utility of PET/CT in the planning of external radiation therapy for prostate cancer. J Nucl Med 59:557–567. https://doi.org/10.2967/jnumed.117.196444 CrossRefPubMedPubMedCentral

31.

Widmark A, Klepp O, Solberg A et al (2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373:8CrossRef

32.

Warde P, Mason M, Ding K et al (2011) Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 378:2104–2111. https://doi.org/10.1016/S0140-6736(11)61095-7 CrossRefPubMedPubMedCentral

33.

James ND, Spears MR, Clarke NW et al (2014) Impact of node status and radiotherapy on failure-free survival in patients with newly-diagnosed non-metastatic prostate cancer: data from > 690 patients in the control arm of the STAMPEDE trial. Int J Radiat Oncol Biol Phys 90:S13. https://doi.org/10.1016/j.ijrobp.2014.05.095 CrossRef

34.

Culp SH, Schellhammer PF, Williams MB (2014) Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 65:1058–1066. https://doi.org/10.1016/j.eururo.2013.11.012 CrossRefPubMed

35.

Antwi S, Everson TM (2014) Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: a population-based, propensity score analysis. Cancer Epidemiol 38:435–441. https://doi.org/10.1016/j.canep.2014.04.002 CrossRefPubMed

36.

Satkunasivam R, Kim AE, Desai M et al (2015) Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis. J Urol 194:378–385. https://doi.org/10.1016/j.juro.2015.02.084 CrossRefPubMedPubMedCentral

37.

Parikh RR, Byun J, Goyal S, Kim IY (2017) Local therapy improves overall survival in patients with newly diagnosed metastatic prostate cancer. Prostate 77:559–572. https://doi.org/10.1002/pros.23294 CrossRefPubMed

38.

Löppenberg B, Dalela D, Karabon P et al (2017) The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis. Eur Urol 72:14–19. https://doi.org/10.1016/j.eururo.2016.04.031 CrossRefPubMed

39.

Leyh-Bannurah S-R, Gazdovich S, Budäus L et al (2017) Local therapy improves survival in metastatic prostate cancer. Eur Urol 72:118–124. https://doi.org/10.1016/j.eururo.2017.03.020 CrossRefPubMed

40.

Steuber T, Berg KD, Røder MA et al (2017) Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? Results from a prospective case-control study. Eur Urol Focus 3:646–649. https://doi.org/10.1016/j.euf.2017.06.016 CrossRefPubMed

41.

Cho Y, Chang JS, Rha KH et al (2016) Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis? PLoS One 11:e0147191. https://doi.org/10.1371/journal.pone.0147191 CrossRefPubMedPubMedCentral

42.

Rusthoven CG, Jones BL, Flaig TW et al (2016) Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol 34:2835–2842. https://doi.org/10.1200/JCO.2016.67.4788 CrossRefPubMed

43.

Gratzke C, Engel J, Stief CG (2014) Role of radical prostatectomy in metastatic prostate cancer: data from the munich cancer registry. Eur Urol 66:602–603. https://doi.org/10.1016/j.eururo.2014.04.009 CrossRefPubMed

44.

Boevé LMS, Hulshof MCCM, Vis AN et al (2018) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. https://doi.org/10.1016/j.eururo.2018.09.008 CrossRefPubMed

45.

Parker CC, James ND, Brawley CD et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. https://doi.org/10.1016/S0140-6736(18)32486-3 CrossRefPubMedPubMedCentral

46.

Sweeney CJ, Chen Y-H, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373:737–746. https://doi.org/10.1056/NEJMoa1503747 CrossRefPubMedPubMedCentral

47.

Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36:446–453. https://doi.org/10.1200/JCO.2017.75.4853 CrossRefPubMed

48.

O’Shaughnessy MJ, McBride SM, Vargas HA et al (2017) A Pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer. Urology 102:164–172. https://doi.org/10.1016/j.urology.2016.10.044 CrossRefPubMed

49.

Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10. https://doi.org/10.1200/JCO.1995.13.1.8 CrossRefPubMed

50.

Soloway MS, Hardeman SW, Hickey D et al (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61:195–202CrossRefPubMed

51.

Singh D, Yi WS, Brasacchio RA et al (2004) Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys 58:3–10. https://doi.org/10.1016/S0360-3016(03)01442-1 CrossRefPubMed

Title: Treatment of the primary tumor in metastatic prostate cancer
Authors: Ye Yuan
Amar U. Kishan
Nicholas G. Nickols
Publication date: 01-12-2019
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 12/2019
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2552-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Treatment of the primary tumor in metastatic prostate cancer

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2019

Preputial lichen sclerosus: a rare and easily ignored initial clinical presentation of newly diagnosed diabetes mellitus

CD163+ macrophages predict a poor prognosis in patients with primary T1 high-grade urothelial carcinoma of the bladder

Clinical significance of cystoscopic urethral stricture recurrence after anterior urethroplasty: a multi-institution analysis from Trauma and Urologic Reconstructive Network of Surgeons (TURNS)

Perioperative management of direct oral anticoagulants in patients undergoing radical prostatectomy: results of a prospective assessment

Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection

Patients choose certainty over burden in bladder cancer surveillance